|
|
|
Liver Clinical Trials |
|
Thank you for your interest in clinical trials for Liver
Please click "Search" to find Liver clinical trials and medical research studies.
If you receive too many study listings you may enter your zip code to find the locations closest to you.
|
|
|
|
|
Results from Clinical Connection:
|
|
|
|
Your search returned 2 studies:
|
|
|
|
|
Results from other databases:
|
|
Your search returned over 250 results. The top 250 results are being displayed. Please use
additional keywords or decrease the search distance. |
|
Your search returned 250 studies:
- 3-Dimensional Conformal Radiation Therapy, Arterial Embolization, and Tumor Cell Vaccine in Treating Patients With Unresectable, Recurrent, or Metastatic Primary Liver Cancer or Pancreatic Cancer - NCT00553683-07101
Conditions: Liver Cancer - Pancreatic Cancer
Location: Newark, NJ
- 4D PET/CT Imaging in Lung and Colorectal Cancer With Liver Metastasis - NCT00862680-77030
Conditions: Colorectal Cancer - Lung Cancer - Liver Cancer
Location: Houston, TX
- A Case Control Study Evaluating the Prevalence of Non-Alcoholic Fatty Liver Disease Among Patients With Psoriasis - NCT00930384-20037
Conditions: Psoriasis - Nonalcoholic Fatty Liver Disease
Location: Washington, DC
- A Multi-Center Group to Study Acute Liver Failure in Children - NCT00986648-02115
Conditions: Acute Liver Failure - Hepatic Encephalopathy
Location: Boston, MA
- A Multi-Center Group to Study Acute Liver Failure in Children - NCT00986648-10029
Conditions: Acute Liver Failure - Hepatic Encephalopathy
Location: New York, NY
- A Multi-Center Group to Study Acute Liver Failure in Children - NCT00986648-10032
Conditions: Acute Liver Failure - Hepatic Encephalopathy
Location: New York, NY
- A Multi-Center Group to Study Acute Liver Failure in Children - NCT00986648-15224
Conditions: Acute Liver Failure - Hepatic Encephalopathy
Location: Pittsburgh, PA
- A Multi-Center Group to Study Acute Liver Failure in Children - NCT00986648-19104
Conditions: Acute Liver Failure - Hepatic Encephalopathy
Location: Philadelphia, PA
- A Multi-Center Group to Study Acute Liver Failure in Children - NCT00986648-21287
Conditions: Acute Liver Failure - Hepatic Encephalopathy
Location: Baltimore, MD
- A Multi-Center Group to Study Acute Liver Failure in Children - NCT00986648-30322
Conditions: Acute Liver Failure - Hepatic Encephalopathy
Location: Atlanta, GA
- A Multi-Center Group to Study Acute Liver Failure in Children - NCT00986648-45229
Conditions: Acute Liver Failure - Hepatic Encephalopathy
Location: Cincinnati, OH
- A Multi-Center Group to Study Acute Liver Failure in Children - NCT00986648-46202
Conditions: Acute Liver Failure - Hepatic Encephalopathy
Location: Indianapolis, IN
- A Multi-Center Group to Study Acute Liver Failure in Children - NCT00986648-48109
Conditions: Acute Liver Failure - Hepatic Encephalopathy
Location: Ann Arbor, MI
- A Multi-Center Group to Study Acute Liver Failure in Children - NCT00986648-60614
Conditions: Acute Liver Failure - Hepatic Encephalopathy
Location: Chicago, IL
- A Multi-Center Group to Study Acute Liver Failure in Children - NCT00986648-63110
Conditions: Acute Liver Failure - Hepatic Encephalopathy
Location: St. Louis, MO
- A Multi-Center Group to Study Acute Liver Failure in Children - NCT00986648-75235
Conditions: Acute Liver Failure - Hepatic Encephalopathy
Location: Dallas, TX
- A Multi-Center Group to Study Acute Liver Failure in Children - NCT00986648-77030
Conditions: Acute Liver Failure - Hepatic Encephalopathy
Location: Houston, TX
- A Multi-Center Group to Study Acute Liver Failure in Children - NCT00986648-80218
Conditions: Acute Liver Failure - Hepatic Encephalopathy
Location: Denver, CO
- A Multi-Center Group to Study Acute Liver Failure in Children - NCT00986648-94143
Conditions: Acute Liver Failure - Hepatic Encephalopathy
Location: San Francisco, CA
- A Multi-Center Group to Study Acute Liver Failure in Children - NCT00986648-98105
Conditions: Acute Liver Failure - Hepatic Encephalopathy
Location: Seattle, WA
- A Non-Randomized Study of Internal Radiation Therapy to the Liver in Patients With Primary Liver Cancer for Whom Surgery is Not Possible. - NCT00152087-33607
Conditions: Liver Cancer
Location: Tampa, FL
- A Phase 2, Dose-Finding, Cross-Over Study to Evaluate the Effect of a NES/E2 Transdermal Gel Delivery on Ovulation Suppression in Normal Ovulating Women - NCT00796133-90033
Conditions: Ovulation
Location: Los Angeles, CA
- A Phase I Study of GC33 in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma) - NCT00746317-02114
Conditions: Advanced or Metastatic HCC
Location: Boston, MA
- A Phase I Study of GC33 in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma) - NCT00746317-02115A
Conditions: Advanced or Metastatic HCC
Location: Boston, MA
- A Phase I Study of GC33 in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma) - NCT00746317-02115B
Conditions: Advanced or Metastatic HCC
Location: Boston, MA
- A Phase I Study of GC33 in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma) - NCT00746317-48201
Conditions: Advanced or Metastatic HCC
Location: Detroit, MI
- A Phase I Study of GC33 in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma) - NCT00746317-90033
Conditions: Advanced or Metastatic HCC
Location: Los Angeles, CA
- A Phase I Study of GC33 in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma) - NCT00746317-98104
Conditions: Advanced or Metastatic HCC
Location: Seattle, WA
- A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure - NCT00721045-15213
Conditions: Heart Failure
Location: Pittsburgh, PA
- A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure - NCT00721045-55407
Conditions: Heart Failure
Location: Minneapolis, MN
- A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure - NCT00721045-77030
Conditions: Heart Failure
Location: Houston, TX
- A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure - NCT00721045-85297
Conditions: Heart Failure
Location: Gilbert, AZ
- A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure - NCT00721045-92037
Conditions: Heart Failure
Location: La Jolla, CA
- A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure - NCT00721045-98122
Conditions: Heart Failure
Location: Seattle, WA
- A Phase II Study of Intra-arterial Chemotherapy With Cisplatin and Mitomycin-C in Patients With Hepatocellular Carcinoma - NCT00183885-90033
Conditions: Hepatocellular Carcinoma - Liver Cancer
Location: Los Angeles, CA
- A Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors in Breast, Lung, Renal, and Adrenal Cancers - NCT01086696-20892
Conditions: Breast Cancer - Lung Cancer - Renal Cancer - Adrenal Cancer
Location: Bethesda, MD
- A Pilot Study of Siliphos in Adults With Non-Alcoholic Steatohepatitis (NASH) - NCT00443079-92103
Conditions: Fatty Liver
Location: San Diego, CA
- A Prospective Study on the Tolerability and Efficacy of the de Novo Use of Myfortic in Liver Transplant Recipients - NCT00336817-15213
Conditions: Immunosuppression
Location: Pittsburgh, PA
- A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase® - NCT0092
Conditions: Hunter Syndrome
Location: Chapel Hill, NC
- A Safety and Efficacy Study to Determine if Giving Intravenous Fish Oil Helps Children With Liver Disease - NCT00969332-90095
Conditions: Parenteral Nutrition Associated Cholestasis
Location: Los Angeles, CA
- A Study Comparing Two Spinal Techniques for for Cesarean Delivery Anesthesia - NCT00990574-94305
Conditions: Hypotension - Headache
Location: Stanford, CA
- A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction - NCT00437424-35294
Conditions: Carcinoma, Hepatocellular
Location: Birmingham, AL
- A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction - NCT00437424-44106
Conditions: Carcinoma, Hepatocellular
Location: Clleveland, OH
- A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction - NCT00437424-78229
Conditions: Carcinoma, Hepatocellular
Location: San Antonio, TX
- A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction - NCT00437424-90033
Conditions: Carcinoma, Hepatocellular
Location: Los Angeles, CA
- A Study of Different Formulations of the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma - NCT00967811-94025
Conditions: Glaucoma - Ocular Hypertension
Location: Menlo Park, CA
- A Study of IMC-A12 in Combination With Sorafenib in Patients With Advanced Cancer of the Liver - NCT00906373-10032
Conditions: Hepatocellular Carcinoma
Location: New York, NY
- A Study of IMC-A12 in Combination With Sorafenib in Patients With Advanced Cancer of the Liver - NCT00906373-19104
Conditions: Hepatocellular Carcinoma
Location: Philadelphia, PA
- A Study of IMC-A12 in Combination With Sorafenib in Patients With Advanced Cancer of the Liver - NCT00906373-60611
Conditions: Hepatocellular Carcinoma
Location: Chicago, IL
- A Study of IMC-A12 in Combination With Sorafenib in Patients With Advanced Cancer of the Liver - NCT00906373-70006
Conditions: Hepatocellular Carcinoma
Location: Metairie, LA
- A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area - NCT00913757-
Conditions: Carcinoma, Hepatocellular - Liver Cirrhosis, Alcoholic - Hepatitis, Alcoholic - Hepatitis, Chronic - Hepatitis, Viral, Human
Location: Baltimore, MD
- A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area - NCT00913757-20892
Conditions: Carcinoma, Hepatocellular - Liver Cirrhosis, Alcoholic - Hepatitis, Alcoholic - Hepatitis, Chronic - Hepatitis, Viral, Human
Location: Bethesda, MD
- A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area - NCT00913757-21205
Conditions: Carcinoma, Hepatocellular - Liver Cirrhosis, Alcoholic - Hepatitis, Alcoholic - Hepatitis, Chronic - Hepatitis, Viral, Human
Location: Baltimore, MD
- A Study to Assess PV-10 Chemoablation of Cancer of the Liver - NCT00986661-92123
Conditions: Cancer Metastatic to the Liver - Recurrent Hepatocellular Carcinoma
Location: San Diego, CA
- A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver - NCT00803647-15212
Conditions: Metastatic Colorectal Cancer
Location: Pittsburgh, PA
- A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere® - NCT00877136-92868
Conditions: Liver Tumors - Hepatocellular Carcinoma - Hepatoma - Neoplasms
Location: Orange, CA
- A Trial of Bed Versus Stirrups Delivery in Nulliparous Women for Prevention of Perineal Lacerations - NCT00895973-75235
Conditions: Perineal Lacerations
Location: Dallas, TX
- A2ALL Human Liver Explants for HIF-1 Alpha Analysis/Comparison (HIF HCC) - NCT00866957-60611
Conditions: Liver Cancer
Location: Chicago, IL
- Abdominal MR Imaging at 3.0T: Sequence Optimization and Implementation - NCT01007357-68198
Conditions: Diffuse and Focal Abnormalities of the Liver and Pancreas
Location: Omaha, NE
- Active Management Of Risk In Pregnancy At Term to Reduce Rate of Cesarean Deliveries - NCT00598260-19141
Conditions: Pregnancy
Location: Philadelphia, PA
- Acupuncture for Promotion of Timely Delivery - NCT00379327-19805
Conditions: Delivery, Obstetric
Location: Wilmington, DE
- An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-grade Glioma - NCT00880061-20892
Conditions: Brain Neoplasm - Glioma
Location: Bethesda, MD
- Anesthetic Effect of Lidocaine/Epinephrine Solution Delivered Via Iontophoresis to External Auditory Apparatus - NCT00941993-30309
Conditions: Acute Otitis Media - Chronic Otitis Media - Recurrent Acute Otitis Media
Location: Atlanta, GA
- Assessment of Insulin Resistance, NAFLD, Predictors of CV Morbidity, and Subcutaneous Adipose and Visceral Adipose Gene Expression in Patients Undergoing Gastric Bypass Surgery - NCT01007955-01655
Conditions: Morbid Obesity - Insulin Resistance - Non-Alcoholic Fatty Liver Disease
Location: Worcester, MA
- Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI - NCT00539253-21287
Conditions: Hepatocellular Carcinoma
Location: Baltimore, MD
- Assessment of Systemically Administered Torisel Delivery to Brain Tumors by Intratumoral Microdialysis - NCT00949026-30322
Conditions: Brain Neoplasms
Location: Atlanta, GA
- AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer - NCT00427973-02114
Conditions: Liver Cancer
Location: Boston, MA
- AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer - NCT00427973-02115
Conditions: Liver Cancer
Location: Boston, MA
- AZD6244 in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00550719-23298
Conditions: Liver Cancer
Location: Richmond, VA
- AZD6244 in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00550719-27599
Conditions: Liver Cancer
Location: Chapel Hill, NC
- AZD6244 in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00550719-30322
Conditions: Liver Cancer
Location: Atlanta, GA
- AZD6244 in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00550719-33612
Conditions: Liver Cancer
Location: Tampa, FL
- AZD6244 in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00550719-37232
Conditions: Liver Cancer
Location: Nashville, TN
- BCG Vaccination Delivered Intradermally, Orally and by Combined Routes - NCT00396370-63104
Conditions: Tuberculosis
Location: St. Louis, MO
- Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery - NCT00335829-21231
Conditions: Liver Cancer
Location: Baltimore, MD
- Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer - NCT00881751-29425
Conditions: Liver Cancer
Location: Charleston, SC
- Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer - NCT00881751-37203
Conditions: Liver Cancer
Location: Nashville, TN
- Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer - NCT00881751-90033
Conditions: Liver Cancer
Location: Los Angeles, CA
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-16801
Conditions: Liver Cancer
Location: State College, PA
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-17822
Conditions: Liver Cancer
Location: Danville, PA
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-18201
Conditions: Liver Cancer
Location: Hazleton, PA
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-18711
Conditions: Liver Cancer
Location: Wilkes-Barre, PA
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-48060
Conditions: Liver Cancer
Location: Port Huron, MI
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-48093
Conditions: Liver Cancer
Location: Warren, MI
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-48106A
Conditions: Liver Cancer
Location: Ann Arbor, MI
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-48106B
Conditions: Liver Cancer
Location: Ann Arbor, MI
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-48123
Conditions: Liver Cancer
Location: Dearborn, MI
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-48154
Conditions: Liver Cancer
Location: Livonia, MI
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-48236
Conditions: Liver Cancer
Location: Grosse Pointe Woods, MI
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-48341
Conditions: Liver Cancer
Location: Pontiac, MI
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-48503A
Conditions: Liver Cancer
Location: Flint, MI
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-48503B
Conditions: Liver Cancer
Location: Flint, MI
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-48601
Conditions: Liver Cancer
Location: Saginaw, MI
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-48912
Conditions: Liver Cancer
Location: Lansing, MI
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-49017
Conditions: Liver Cancer
Location: Battle Creek, MI
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-49201
Conditions: Liver Cancer
Location: Jackson, MI
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-49307
Conditions: Liver Cancer
Location: Big Rapids, MI
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-49443
Conditions: Liver Cancer
Location: Muskegon, MI
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-49503A
Conditions: Liver Cancer
Location: Grand Rapids, MI
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-49503B
Conditions: Liver Cancer
Location: Grand Rapids, MI
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-49503C
Conditions: Liver Cancer
Location: Grand Rapids, MI
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-49519
Conditions: Liver Cancer
Location: Wyoming, MI
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-49684
Conditions: Liver Cancer
Location: Traverse City, MI
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-50307
Conditions: Liver Cancer
Location: Des Moines, IA
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-50309A
Conditions: Liver Cancer
Location: Des Moines, IA
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-50309B
Conditions: Liver Cancer
Location: Des Moines, IA
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-50309C
Conditions: Liver Cancer
Location: Des Moines, IA
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-50314A
Conditions: Liver Cancer
Location: Des Moines, IA
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-50314B
Conditions: Liver Cancer
Location: Des Moines, IA
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-50316
Conditions: Liver Cancer
Location: Des Moines, IA
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-50325
Conditions: Liver Cancer
Location: Clive, IA
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-51101
Conditions: Liver Cancer
Location: Sioux City, IA
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-51104A
Conditions: Liver Cancer
Location: Sioux City, IA
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-51104B
Conditions: Liver Cancer
Location: Sioux City, IA
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-52722
Conditions: Liver Cancer
Location: Bettendorf, IA
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-55102
Conditions: Liver Cancer
Location: Saint Paul, MN
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-55109
Conditions: Liver Cancer
Location: Maplewood, MN
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-55125
Conditions: Liver Cancer
Location: Woodbury, MN
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-55337
Conditions: Liver Cancer
Location: Burnsville, MN
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-55379
Conditions: Liver Cancer
Location: Shakopee, MN
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-55387
Conditions: Liver Cancer
Location: Waconia, MN
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-55407
Conditions: Liver Cancer
Location: Minneapolis, MN
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-55416A
Conditions: Liver Cancer
Location: Saint Louis Park, MN
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-55416B
Conditions: Liver Cancer
Location: Saint Louis Park, MN
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-55422
Conditions: Liver Cancer
Location: Robbinsdale, MN
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-55432
Conditions: Liver Cancer
Location: Fridley, MN
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-55433
Conditions: Liver Cancer
Location: Coon Rapids, MN
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-55435
Conditions: Liver Cancer
Location: Edina, MN
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-55805A
Conditions: Liver Cancer
Location: Duluth, MN
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-55805B
Conditions: Liver Cancer
Location: Duluth, MN
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-55805C
Conditions: Liver Cancer
Location: Duluth, MN
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-55905
Conditions: Liver Cancer
Location: Rochester, MN
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-56537
Conditions: Liver Cancer
Location: Fergus Falls, MN
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-56601
Conditions: Liver Cancer
Location: Bemidji, MN
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-57105
Conditions: Liver Cancer
Location: Sioux Falls,
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-57117
Conditions: Liver Cancer
Location: Sioux Falls,
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-57701
Conditions: Liver Cancer
Location: Rapid City,
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-58122A
Conditions: Liver Cancer
Location: Fargo, ND
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-58122B
Conditions: Liver Cancer
Location: Fargo, ND
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-58501A
Conditions: Liver Cancer
Location: Bismarck, ND
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-58501B
Conditions: Liver Cancer
Location: Bismarck, ND
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-58501C
Conditions: Liver Cancer
Location: Bismarck, ND
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-58502
Conditions: Liver Cancer
Location: Bismarck, ND
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-59101A
Conditions: Liver Cancer
Location: Billings, MT
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-59101B
Conditions: Liver Cancer
Location: Billings, MT
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-59101C
Conditions: Liver Cancer
Location: Billings, MT
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-59101D
Conditions: Liver Cancer
Location: Billings, MT
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-59107
Conditions: Liver Cancer
Location: Billings, MT
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-59405A
Conditions: Liver Cancer
Location: Great Falls, MT
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-59405B
Conditions: Liver Cancer
Location: Great Falls, MT
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-59501
Conditions: Liver Cancer
Location: Havre, MT
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-59601
Conditions: Liver Cancer
Location: Helena, MT
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-59701
Conditions: Liver Cancer
Location: Butte, MT
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-59715
Conditions: Liver Cancer
Location: Bozeman, MT
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-59801
Conditions: Liver Cancer
Location: Missoula, MT
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-59804
Conditions: Liver Cancer
Location: Missoula, MT
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-59807A
Conditions: Liver Cancer
Location: Missoula, MT
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-59807B
Conditions: Liver Cancer
Location: Missoula, MT
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-59901A
Conditions: Liver Cancer
Location: Kalispell, MT
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-59901B
Conditions: Liver Cancer
Location: Kalispell, MT
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-59901C
Conditions: Liver Cancer
Location: Kalispell, MT
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-61265A
Conditions: Liver Cancer
Location: Moline, IL
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-61265B
Conditions: Liver Cancer
Location: Moline, IL
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-61350A
Conditions: Liver Cancer
Location: Ottawa, IL
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-61350B
Conditions: Liver Cancer
Location: Ottawa, IL
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-61354A
Conditions: Liver Cancer
Location: Peru, IL
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-61354B
Conditions: Liver Cancer
Location: Peru, IL
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-61356A
Conditions: Liver Cancer
Location: Princeton, IL
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-61356B
Conditions: Liver Cancer
Location: Princeton, IL
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-61362
Conditions: Liver Cancer
Location: Spring Valley, IL
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-61401A
Conditions: Liver Cancer
Location: Galesburg, IL
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-61401B
Conditions: Liver Cancer
Location: Galesburg, IL
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-61443
Conditions: Liver Cancer
Location: Kewanee, IL
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-61455A
Conditions: Liver Cancer
Location: Macomb, IL
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-61455B
Conditions: Liver Cancer
Location: Macomb, IL
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-61462A
Conditions: Liver Cancer
Location: Monmouth, IL
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-61462B
Conditions: Liver Cancer
Location: Monmouth, IL
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-61520A
Conditions: Liver Cancer
Location: Canton, IL
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-61520B
Conditions: Liver Cancer
Location: Canton, IL
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-61530A
Conditions: Liver Cancer
Location: Eureka, IL
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-61530B
Conditions: Liver Cancer
Location: Eureka, IL
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-61554
Conditions: Liver Cancer
Location: Pekin, IL
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-61603
Conditions: Liver Cancer
Location: Pekin, IL
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-61614
Conditions: Liver Cancer
Location: Peoria, IL
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-61615A
Conditions: Liver Cancer
Location: Peoria, IL
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-61615B
Conditions: Liver Cancer
Location: Peoria, IL
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-61636
Conditions: Liver Cancer
Location: Peoria, IL
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-61637
Conditions: Liver Cancer
Location: Peoria, IL
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-61701A
Conditions: Liver Cancer
Location: Bloomington, IL
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-61701B
Conditions: Liver Cancer
Location: Bloomington%, IL
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-61761A
Conditions: Liver Cancer
Location: Normal, IL
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-61761B
Conditions: Liver Cancer
Location: Normal, IL
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-61761C
Conditions: Liver Cancer
Location: Normal, IL
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-62321A
Conditions: Liver Cancer
Location: Carthage, IL
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-62321B
Conditions: Liver Cancer
Location: Carthage, IL
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-62644A
Conditions: Liver Cancer
Location: Havana, IL
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-62644B
Conditions: Liver Cancer
Location: Havana, IL
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-66044
Conditions: Liver Cancer
Location: Lawrence, KS
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-66701
Conditions: Liver Cancer
Location: Fort Scott, KS
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-66720
Conditions: Liver Cancer
Location: Chanute, KS
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-67003
Conditions: Liver Cancer
Location: Anthony, KS
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-67042
Conditions: Liver Cancer
Location: El Dorado, KS
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-67068
Conditions: Liver Cancer
Location: Kingman, KS
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-67114
Conditions: Liver Cancer
Location: Newton, KS
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-67124
Conditions: Liver Cancer
Location: Pratt, KS
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-67152
Conditions: Liver Cancer
Location: Wellington, KS
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-67156
Conditions: Liver Cancer
Location: Winfield, KS
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-67208A
Conditions: Liver Cancer
Location: Wichita, KS
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-67208B
Conditions: Liver Cancer
Location: Wichita, KS
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-67214A
Conditions: Liver Cancer
Location: Wichita, KS
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-67214B
Conditions: Liver Cancer
Location: Wichita, KS
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-67214C
Conditions: Liver Cancer
Location: Wichita, KS
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-67301
Conditions: Liver Cancer
Location: Independence, KS
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-67357
Conditions: Liver Cancer
Location: Parsons, KS
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-67401
Conditions: Liver Cancer
Location: Salina, KS
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-67801
Conditions: Liver Cancer
Location: Dodge City, KS
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-67901
Conditions: Liver Cancer
Location: Liberal, KS
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-74136
Conditions: Liver Cancer
Location: Tulsa, OK
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-82801
Conditions: Liver Cancer
Location: Sheridan, WY
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer - NCT00867321-85259
Conditions: Liver Cancer
Location: Scottsdale, AZ
- Biological Markers of Disease in the Prediction of Preterm Delivery, Preeclampsia and Intra-Uterine Growth Retardation: A Longtitudinal Study - NCT00340899-
Conditions: Maternal Fetal Factors
Location: Detroit, MI
- Biological Markers of Disease in the Prediction of Preterm Delivery, Preeclampsia and Intra-Uterine Growth Retardation: A Longtitudinal Study - NCT00340899-48073
Conditions: Maternal Fetal Factors
Location: Royal Oak, MI
- Biomarker Study With SCH 900105 (Study P05670AM1) - NCT00969410-07033
Conditions: Neoplasms Metastasis - Liver Metastases
Location: Kenilworth, NJ
- Biomarkers and Radiation Side Effects in Patients Undergoing Radiation Therapy for Gastrointestinal Cancer - NCT00452946-20892
Conditions: Colorectal Cancer - Esophageal Cancer - Extrahepatic Bile Duct Cancer - Gallbladder Cancer - Gastric Cancer - Gastrointestinal Complications - Liver Cancer - Pancreatic Cancer - Radiation Toxicity
Location: Bethesda, MD
- Bone Marrow Radiation Therapy Followed by Busulfan, Melphalan, Thiotepa, and an Autologous Stem Cell Transplant in Treating Patients With High-Risk or Relapsed Solid Tumors - NCT00623077-55455
Conditions: Brain and Central Nervous System Tumors - Kidney Cancer - Liver Cancer - Retinoblastoma - Sarcoma - Unspecified Adult Solid Tumor, Protocol Specific - Unspecified Childhood Solid Tumor, Protocol Specific
Location: Minneapolis, MN
- Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction - NCT00091117-15232
Conditions: Liver Cancer - Lymphoma - Unspecified Adult Solid Tumor, Protocol Specific
Location: Pittsburgh, PA
- Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction - NCT00091117-44106
Conditions: Liver Cancer - Lymphoma - Unspecified Adult Solid Tumor, Protocol Specific
Location: Cleveland, OH
- Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction - NCT00091117-48201
Conditions: Liver Cancer - Lymphoma - Unspecified Adult Solid Tumor, Protocol Specific
Location: Detroit, MI
- Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction - NCT00091117-53792
Conditions: Liver Cancer - Lymphoma - Unspecified Adult Solid Tumor, Protocol Specific
Location: Madison, WI
- Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction - NCT00091117-78229
Conditions: Liver Cancer - Lymphoma - Unspecified Adult Solid Tumor, Protocol Specific
Location: San Antonio, TX
- Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction - NCT00091117-91010
Conditions: Liver Cancer - Lymphoma - Unspecified Adult Solid Tumor, Protocol Specific
Location: Duarte, CA
- Brachytherapy Radiation Directly to the Liver in Breast Cancer Patients With Metastatic to Liver - NCT00891800-33607
Conditions: Breast Cancer Metastatic to the Liver
Location: Tampa, FL
- Cesarean Delivery and Post-Operative Pain Management With Local Anesthesia - NCT00298571-33606
Conditions: Pain, Postoperative
Location: Tampa, FL
- Cetuximab and/or Dasatinib in Treating Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery - NCT00835679-37064
Conditions: Colorectal Cancer - Metastatic Cancer
Location: Nashville, TN
- Cetuximab and/or Dasatinib in Treating Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery - NCT00835679-37232
Conditions: Colorectal Cancer - Metastatic Cancer
Location: Nashville, TN
- Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery - NCT01004978-08043
Conditions: Liver Cancer
Location: Voorhees, NJ
- Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery - NCT01004978-08053
Conditions: Liver Cancer
Location: Marlton, NJ
- Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery - NCT01004978-19111
Conditions: Liver Cancer
Location: Philadelphia, PA
- Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery - NCT01004978-24740
Conditions: Liver Cancer
Location: Princeton, WV
- Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery - NCT01004978-29605
Conditions: Liver Cancer
Location: Greenville, SC
- Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery - NCT01004978-29615
Conditions: Liver Cancer
Location: Greenville, SC
- Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery - NCT01004978-29650
Conditions: Liver Cancer
Location: Greer, SC
- Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery - NCT01004978-37920
Conditions: Liver Cancer
Location: Knoxville, TN
- Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery - NCT01004978-50309A
Conditions: Liver Cancer
Location: Des Moines, IA
- Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery - NCT01004978-50309B
Conditions: Liver Cancer
Location: Des Moines, IA
- Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery - NCT01004978-50309C
Conditions: Liver Cancer
Location: Des Moines, IA
- Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery - NCT01004978-50314A
Conditions: Liver Cancer
Location: Des Moines, IA
- Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery - NCT01004978-50314B
Conditions: Liver Cancer
Location: Des Moines, IA
- Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery - NCT01004978-50316
Conditions: Liver Cancer
Location: Des Moines, IA
- Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery - NCT01004978-50325
Conditions: Liver Cancer
Location: Clive, IA
|
|
|
|
|
Didn't find what you were looking for? Try these alternatives:
Become A Member: To be notified of upcoming clinical trials in your
area please create a free member account.
Browse Studies: If you would like to browse all featured clinical trials
please Browse Studies.
Message Board: Join the discussion in our Health
and Clinical Trials Message Board.
|
|
|